Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03710551
Other study ID # 16.28.INF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 26, 2018
Est. completion date July 21, 2019

Study information

Verified date February 2021
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the stool composition and GI tolerance of an experimental formula with a new fat blend plus L. reuteri vs control formula.


Description:

Double-blind, randomized, controlled clinical trial. The purpose of this study is to evaluate the stool composition and GI tolerance of 140 healthy, term infants fed with an infant formula with a new fat blend plus L. reuteri vs a standard infant formula. All enrolled infants will participate in the trial for approximately 71 days.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date July 21, 2019
Est. primary completion date June 21, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 28 Days
Eligibility Inclusion Criteria: - Written Informed Consent - Infants whose parents/LAR have reached the legal age of majority in the Philippines - Infants whose parent(s)/LAR are willing and able to comply with scheduled visits, and the requirements of the study protocol - Infants whose parent(s)/LAR are able to be contacted directly by telephone throughout the study - Healthy term, singleton infant at birth - Between 21 to 28 days post-natal age at enrollment visit - Weight-for-age = 5th and = 95th percentile according to World Health Organization growth tables/charts - Infants of parent(s)/LAR who have previously made the decision to formula feed their infant at the time of enrollment Exclusion Criteria: - Infants with conditions requiring infant feedings other than those specified in the protocol - Infants receiving complementary foods or liquids - Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results - Infants who are presently receiving or have received medications that could interfere with the interpretation of the study results

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Experimental Infant Formula
Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
Standard Infant Formula
Standard bovine milk-based infant formula, fed ad libitum

Locations

Country Name City State
Philippines Asian Hospital and Medical Center Muntinlupa

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

Philippines, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stool Consistency Score 3-day Gastrointestinal (GI) Symptom and Behavior Diary, a parent-reported symptom diary to record stool consistency and stool frequency over the 3 consecutive days.
A validated 5-point pictorial representation of the consistency of the stool for infants =1 year (1=watery, 2=runny, 3=mushy soft, 4=formed, 5=hard) will be provided in the stool diary for parent(s)/LAR to visually assess the infants' stools.
Stool consistency will be compared between formula groups The baseline stool consistency value will also be included in the model as a covariate.
the percentage of stools in each category (watery, runny, mushy soft, formed, or hard) will be calculated by visit for each infant and then will be summarized using the appropriate descriptive statistics. Figures composed of a series of histograms will be produced for each 3-day stool diary period.
Study Day 57, corresponding to infant age of 78-85 days
Secondary GI Tolerance Infant Gastrointestinal Symptom Questionnaire (IGSQ)
Overall GI symptom burden will be measured with the IGSQ-13 questionnaire. The IGSQ-13 is an interviewer-administered questionnaire which measures how well the infant tolerates his/her feedings from the parent's/caregiver's perspective. The questionnaire is composed of 13 questions, categorized into 5 symptom domains of stooling, vomiting/spitting-up, crying, fuzziness, and flatulence and summed to calculate an index score.
which corresponds to infant age of 21-28, 43-50, and 78-85 days.
Secondary Changes in Weight from baseline to 57 days weight (kg) Study Day 57, corresponding to infant age of 78-85 days
Secondary Changes in Length from baseline to 57 days length (cm) Study Day 57, corresponding to infant age of 78-85 days
Secondary Changes in Head Circumference from baseline to 57 days head circumference (cm) Study Day 57, corresponding to infant age of 78-85 days
See also
  Status Clinical Trial Phase
Completed NCT02598817 - Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula
Completed NCT03387124 - Breastfeeding Study
Completed NCT02670863 - Safety and Efficacy Study N/A